Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 16;9(3):304.
doi: 10.3390/biomedicines9030304.

Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance

Marta Araujo-Castro  1 , Eider Pascual-Corrales  1 , Javier Molina-Cerrillo  2 , Teresa Alonso-Gordoa  2
Affiliations
Review

Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance

Marta Araujo-Castro et al. Biomedicines. .

Abstract

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with limited treatment options in the advanced stages. Immunotherapy offers hope for altering the orthodox management of cancer, and its role in advanced ACC has been investigated in different studies. With the aim clarifying the role of immunotherapy in ACC we performed a comprehensive review about this topic focusing on the predictors of response, efficacy, safety, and the mechanisms of resistance. Five clinical trials with four immune checkpoint inhibitors (pembrolizumab, avelumab, nivolumab, and ipilimumab) have investigated the role of immunotherapy in advanced ACC. Despite, the different primary endpoints used in these studies, the reported rates of overall response rate and progression free survival were generally poor. Three main potential markers of response to immunotherapy in ACC have been described: Expression of PD-1 and PD-L1, microsatellite instability and tumor mutational burden. However, none of them has been validated in prospective studies. Several mechanisms of ACC immunoevasion may be responsible of immunotherapy failure, and a greater knowledge of these mechanisms might lead to the development of new strategies to overcome the immunotherapy resistance. In conclusion, although currently the role of immunotherapy is limited, the identification of immunological markers of response and the implementation of strategies to avoid immunotherapy resistance could improve the efficacy of this therapy.

Keywords: adrenocortical carcinoma; anti-PD-L1; immunotherapy; pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Molecular alterations in adrenocortical carcinoma. IGF2: Insulin-like growth factor 2; LOH: Loss of heterozygosity; PKA: Protein kinase A; WGD: Whole-genome doubling.
Figure 2
Figure 2
Mechanism of action of programmed death-1 (PD-1)/PD-L1 and CTLA-4 immuno checkpoint inhibitors used for adrenocortical carcinoma treatment. Immunotherapy targeting CTLA-4 (ipilimumab), PD-1 (nivolumab, pembrolizumab), and PD-L1 (avelumab) block immune checkpoints (CTLA-4, PD-1, and PD-L1, respectively) and restore antitumor immune response, resulting in tumor cell death via release of cytolytic molecules (e.g., granzyme B, TNF-a, INF-g). APC: professional antigen presenting; TCR: MHC-T cell receptor.
See this image and copyright information in PMC

References

    1. Varghese J., Habra M.A. Update on adrenocortical carcinoma management and future directions. Curr. Opin. Endocrinol. Diabetes Obes. 2017 doi: 10.1097/MED.0000000000000332. - DOI - PubMed
    1. Kerkhofs T.M.A., Verhoeven R.H.A., Van Der Zwan J.M., Dieleman J., Kerstens M.N., Links T.P., Van De Poll-Franse L.V., Haak H.R. Adrenocortical carcinoma: A population-based study on incidence and survival in the Netherlands since 1993. Eur. J. Cancer. 2013 doi: 10.1016/j.ejca.2013.02.034. - DOI - PubMed
    1. Ayala-Ramirez M., Jasim S., Feng L., Ejaz S., Deniz F., Busaidy N., Waguespack S.G., Naing A., Sircar K., Wood C.G., et al. Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care Center. Eur. J. Endocrinol. 2013 doi: 10.1530/EJE-13-0519. - DOI - PMC - PubMed
    1. Fassnacht M., Dekkers O.M., Else T., Baudin E., Berruti A., De Krijger R.R., Haak H.R., Mihai R., Assie G., Terzolo M. European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the study of adrenal tumors. Eur. J. Endocrinol. 2018 doi: 10.1530/EJE-18-0608. - DOI - PubMed
    1. Kerkhofs T.M., Baudin E., Terzolo M., Allolio B., Chadarevian R., Mueller H.H., Skogseid B., Leboulleux S., Mantero F., Haak H.R., et al. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2013 doi: 10.1210/jc.2013-2281. - DOI - PubMed

LinkOut - more resources